Thus, selective serotonin reuptake inhibitors (SSRIs) may have a beneficial role in the pathophysiology of AD [164], ensuring active neuronal signalling is preserved and Aβ and tau fibril deposition are prevented, thereby improving AD. The gene discussed is MAPT; the disease is Alzheimer disease.